Form 6-K Adaptimmune Therapeutics For: Nov 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss
November 13, 2015 8:00 AM ESTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $-0.00, versus (GBP0.01) reported last year. Revenue for the quarter came in at GBP2.6 million, versus GBP944 thousand reported last year.
Adaptimmune is reiterating its cash burn guidance. For the six months ending December... More
